Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. They help people with debilitating and complex conditions that are often difficult to diagnose and treat. They are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, they also established ourselves as a leader in the field of multiple sclerosis. In 2016, their focus expanded to include Sanofi’s programs in oncology and immunology. Their approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, they rapidly grew to become one of the world’s leading biotechnology companies, recognized for their pioneering development of treatments for rare genetic disorders and their innovative contributions to medical science and biomanufacturing.

Boehringer Ingelheim International GmbH manufactures pharmaceutical prodcuts. It offers human and animal health products. The company was founded by Albert Boehringer in 1885 and is headquartered in Ingelheim, Germany.

Bayer HealthCare Ltd., established on 1995-08-25, Business scope includes licensed projects:pharmaceutical production;Pharmaceutical commissioned production;Drug Wholesale;Drug import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business;food sales;Health food production;food production;Production of formula food for special medical purpose;Cosmetic production;Production of hygiene products and single-use medical products;Disinfectant production(Free of Hazardous Chemicals).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)General project:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Medical Research and Experimental Development;Production of Class I Medical Devices;Sales of Class I Medical Devices;Sales of Class II Medical Devices;Cosmetics Wholesale;Cosmetics Retail;internet sales(Except for products that require a license for sale);Food import and export;software development;software sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Manufacturing of computer software, hardware and peripheral equipment;Software outsourcing service;Information Consulting Service(Not including licensing information consulting services);Information Technology Consulting Services;Special Equipment Repair;Import and export;Technology Import and Export;Import and export agency;Sales of hygiene products and single-use medical products;Disinfectant sales(Free of Hazardous Chemicals);Manufacturing of daily chemical products;Sales of daily chemical products.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)(Do not engage in the business activities of projects prohibited and restricted by the industrial policies of the state and this city.)

Organ Technologies was founded to spark a new industrial revolution starting from Japan which is one of the health care’s hottest growth fields: regenerative medicine. Our mission is to promote the health and welfare of people all over the world through our novel bio-engineering technologies designed to produce realistic organs that are functionally equivalent to natural ones.

Amgen Inc. (formerly Applied Molecular Genetics Inc.) is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. In 2018, the company's largest selling product lines were Neulasta, an immunostimulator used to prevent infections in patients undergoing cancer chemotherapy and Enbrel, a tumor necrosis factor blocker used in the treatment of rheumatoid arthritis and other autoimmune diseases. Other products include Epogen, Aranesp, Sensipar/Mimpara, Nplate, Vectibix, Prolia and XGEVA.

DSM IP Assets BV, a subsidiary of Koninklijke DSM NV, is a company headquartered in Heerlen, the Netherlands, that develops and produces nutrition, pharmacy & material science products.

Shanghai Ruiyu Biotechnology Co., Ltd., established on 2009-06-23, Business scope includes licensed projects:Import and export;Technology Import and Export.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments) General project:Biotechnology field,Medical testing field,Environmental protection field,Technology development in the field of intelligent systems,technical consulting,Technical Services,technology transfer;Instrumentation,Production of laboratory equipment and consumables,Sales;Integrated Development of Computer Software and Hardware System,Sales,repair;Sales of chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,firecrackers,civilian explosives,precursor chemicals);Non-residential real estate leases.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

ABLE provides renewable energy, robot development, plant construction, and maintenance services. They also provide consulting services for customer installation, business feasibility studies, design and engineering, application procedures, and procurement of equipment.

Teijin Ltd. engages in the management of its group companies that are involved in the environment and energy, safety and protection, information and electronics, transportation, and healthcare businesses. It operates through the following segments: Materials, Healthcare, and Others. The Materials segment handles the manufacture and sale of polyester, aramid, and carbon fiber products as well as plastic and resin products from polycarbonate resin and polyester film. The Healthcare segment deals with the manufacture and sale of pharmaceuticals and home medical equipment. It also provides home healthcare services. The Others segment offers information technology services. The company was founded by Seita Kumura, Itsuzo Hata, and Naokichi Kaneko on June 17, 1918 and is headquartered in Osaka, Japan.

Coherus Biosciences is a biopharmaceutical company that engages in the development, manufacture, and commercialization of biologic therapeutics. The company develops biologic medicines primarily for the treatment of oncology and inflammatory diseases. It focuses on process science, analytical characterization, protein production, and clinical-regulatory development. Its pipeline includes Immunology, anti-tumor necrosis factor (Anti-TNF) biosimilar candidates; Ophthalmology biosimilar candidates; and Oncology Biosimilar candidates.

Cook, Inc. develops healthcare devices. The company integrates minimally invasive medical device design, biopharma, gene and cell therapy, and biotech to enhance patient safety as well as improve clinical outcomes in the fields of aortic intervention, interventional cardiology, critical care medicine, gastroenterology, radiology, peripheral vascular, bone access & oncology, surgery and soft tissue repair, urology, and assisted reproductive technology, gynecology as well as high-risk obstetrics. The company is located in Bloomington, IN.

Glycotope GmbH operates as a biotechnology company to develop pharmaceutical therapeutics and nutrition additives. It focuses on the optimization and humanization of therapeutically relevant sugar structures on biopharmaceuticals known as glycosylation and on the development of innovative antibodies targeting glycostructures on cell surfaces. The company was founded by Steffen Goletz and Andreas Eckert in Febraury 2001 and is headquartered in Berlin, Germany.

Rohm and Haas Company is a manufacturer of speciality chemicals for end use markets such as building and construction, electronic devices, packaging, household and personal care products. Headquartered in Philadelphia, the company is organised into three business groups of Specialty Materials, Performance Materials and Electronic Materials, and also has two stand-alone businesses of Powder Coatings and Salt. Formerly a Fortune 500 Company, Rohm and Haas employs more than 17,000 people in 27 countries, with its last sales revenue reported as an independent company at US$8.9 billion. Dow Chemical Company bought Rohm and Haas for $15 billion in 2009.

Bristol-Myers Squibb Company, through its subsidiaries, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of pharmaceuticals and nutritional products. The company operates in two segments, Pharmaceuticals, and Nutritionals. The Nutritionals segment is operated through the company's subsidiary Mead Johnson Nutrition Company (Mead Johnson). The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business.

CEVEC is a center of expertise for the production of biopharmaceuticals using a unique human cell-based expression system. CAP-Go enables the production of proteins “beyond antibodies”. Complex, glycosylated proteins represent a significant portion of the human proteome and are notoriously difficult to express in conventional cell lines such as CHO. The CAP-Go expression platform comprises a portfolio of glyco-optimized human suspension cell lines for the highly efficient production of a broad range of difficult to express recombinant proteins with authentic human post-translational modifications or on demand tailor-made glycosylation patterns.

Takasago Electric, Inc. engages in the manufacture and sale of fluid control equipment. It supplies valves, pumps, and manifolds. Its products are used in the development of analyzers. The company was founded on July 1, 1959 and is headquartered in Nagoya, Japan.

Guangzhou Maipu Regenerative Medicine Technology Co., Ltd., established on 2008-09-02, Business scope includes engineering and technology research and experimental development;Medical Research and Experimental Development;3Dprint service;3DPrint base material sales;additive manufacturing;Additive Manufacturing Equipment Manufacturing;Additive Manufacturing Equipment Sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Manufacture of teaching models and teaching aids;Industrial Design Services;software sales;software development;synthetic material manufacturing(Free of Hazardous Chemicals);General equipment manufacturing(Does not include special equipment manufacturing);Labor service(Does not include labor dispatch);Sales of Class II Medical Devices;Non-residential real estate leases;property management;Entrepreneurial Space Services;Technology intermediary service;Park Management Services;Conference and Exhibition Services;Business Management Consulting;Information Consulting Service(Not including licensing information consulting services);car park service;Import and export;Production of Class II Medical Devices;Production of Class III Medical Devices;Class III medical device business

Regenetech, Inc. develops and distributes tissue regeneration technology. It provides research and development services for adult stem cells expansion and therapeutic applications. The firm offers umbilical cord and peripheral blood expansion, bone regeneration, and biomolecules producing therapeutic technologies. The company was founded in April, 2002 and is headquartered in Houston, TX.

Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA.